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Background: Management of pulmonary hypertension, a potentially fatal 
complication of operations to correct congenital heart disease, has evolved 
through the last 15 years. Monitoring of pulmonary arterial pressure and 
mixed venous aturation became available, and prophylactic use of a-block- 
ers and other vasodilators increased. This study examines ri k factors for 
morbidity and mortality from pulmonary hypertension after operations to 
correct congenital heart disease and evaluates the impact of management 
changes on outcomes. Methods: By means of multivariable logistic regres- 
sion analysis, 880 high-risk patients with congenital heart disease (of 2484 
patients undergoing cardiopulmonary b pass between January 1980 and 
December 1994) were analyzed to determine which were at risk for 
postoperative pulmonary hypertension and its associated morbidity and 
mortality. Results: Patients with atrioventricular canal (n = 182), truncus 
arteriosus (n = 47), total anomalous pulmonary venous connection (n = 
90), transposition of great arteries (n = 97), hypoplastic left heart 
syndrome (n = 50), and ventricular septal defect (n = 414) demonstrated 
a higher risk of postoperative pulmonary hypertension. By multivariable 
logistic regression, preoperative pulmonary hypertension (p < 0.0001), 
absence of mixed venous saturation monitoring (p < 0.0001), and absence 
of prophylactic a-blockade (p = 0.0004) significantly increased postoper- 
ative pulmonary hypertension. Preoperative pulmonary hypertension (p < 
0.001) and absence of prophylactic a-blockers (p = 0.0004) were significant 
risk factors for in-hospital death related to pulmonary hypertension. 
Repair at older age (except in the case of total anomalous pulmonary 
venous connection) was a significant risk for postoperative pulmonary 
hypertension (p = 0.03). Conclusion: Mixed venous saturation monitoring 
and a-receptor blockade reduced the incidence of pulmonary hypertension 
after operations for congenital heart disease. Early definitive repair 
reduced morbidity and mortality from postoperative pulmonary hyperten- 
sion. (J Thorac Cardiovasc Surg 1996;112:1600-9) 
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R eports of surgical management of complex con- genital heart disease during the past 15 years 
indicate a general trend of steady decline in perioper- 
ative mortality. However, pulmonary hypertension as a 
result of increased pulmonary vascular esistance re- 
mains one of the most important determinants of 
perioperative morbidity and mortality, as well as long- 
term survival after cardiac operations. 1-6 This poten- 
tially fatal complication occurs most commonly, but 
not exclusively, among neonates and infants who are 
intubated after operation for the repair of a congenital 
cardiac defect. Few studies, however, have analyzed 
incidence of and risk factors for development of post- 
operative pulmonary hypertension among various 
forms of complex congenital heart disease. 
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Monitoring and management of postoperative 
pulmonary hypertension have been evolving in our 
institution since the middle 1980s. Major changes 
include monitoring of pulmonary arterial pressures 
and mixed venous saturation (SVO2) and prophylaxis 
with o~-blockers (chlorpromazine and prazosin) and 
other vasodilators (nitroglycerin and sodium nitro- 
prusside). The purpose of this study was to deter- 
mine which patients were at high risk for postoper- 
ative pulmonary hypertensive events and to analyze 
risk factors for morbidity and mortality from post- 
operative pulmonary hypertension. 
Patients and method 
Patients. Two thousand four hundred eighty-four pa- 
tients with congenital heart disease were operated on with 
cardiopulmonary b pass between January 1980 and De- 
cember 1994 at James W. Riley Hospital for Children at 
Indiana University Medical Center. High-risk groups were 
defined as those in which the incidence of postoperative 
pulmonary hypertensive events was at least 5% of total 
cases or those with a hospital mortality rate of at least 5% 
among patients in whom postoperative pulmonary hyper- 
tension developed. Patients with rare congenital heart 
diseases (fewer than 10 cases in this 15-year experience) 
were excluded from this analysis to lessen the chance of a 
type II statistical error. Children who received palliation 
at other institutions before being referred to our center 
were also excluded. Patients with other associated cardio- 
vascular and noncardiovascular esions were included. 
Preoperative valuation. Preoperative diagnostic tech- 
niques have evolved during the last 15 years. Cardiac 
catheterization was performed for most patients treated 
before 1989. Echocardiography as been performed rou- 
tinely since 1978. In most patients with hypoplastic left 
heart syndrome or transposition of the great arteries, 
diagnosis was made by echocardiography. Since 1990, 
atrioventricular canal (n = 14) and total anomalous 
pulmonary venous connection (n = 13) have been diag- 
nosed by echocardiography alone. 
Preoperative pulmonary hypertension was defined as a 
systolic pulmonary arterial pressure greater than 50% of 
systemic pressure. Prematurity was defined as birth at less 
than 36 weeks of gestational age or birth weight lower 
than 2500 gm. 
Operative management. Our operative management 
has evolved uring the last 15 years. A median sternotomy 
is performed, any adhesions present are freed, and the 
external cardiac anatomy is assessed. Cannulation is ac- 
complished by using the ascending aorta for aortic inflow 
and separate caval cannulas inserted through the right 
atrial appendage, superior vena cava, or both. Cardiopul- 
monary bypass is instituted at a flow rate of 2.4 
L- min -1 • m -2, and the perfusate iscooled to 20 ° to 28 ° C 
in most cases. For patients that require circulatory arrest, 
a single venous cannula is used and the repair is per- 
formed after the perfusate is cooled to 15°C and main- 
tained for 15 minutes. The left side of the heart is vented 
with a catheter inserted through the apex of the left 
ventricle or through the left atrial appendage. Cold crys- 
talloid cardioplegic solution is injected at a total volume of 
15 ml/kg. Topical hypothermia is added. The infusion of 
cardioplegic solution is repeated at 20- to 25-minute 
intervals, sooner if electrical activity is noted. 
Intraoperative postrepair evaluation and monitoring. 
As patients are being warmed and weaned from bypass, 
left atrial, pulmonary arterial, and right atrial oximetric 
monitoring catheters are inserted for intraoperative and 
postoperative monitoring for those patients at high risk 
for postoperative pulmonary hypertension. For the pa- 
tients without preoperative pulmonary hypertension, a 
right atrial oximetric atheter alone is used for monitoring 
SVO 2. 
Intravenous nitroglycerin at a dose of 0.5 to 10 
t~g" kg 1 min-1 and nitroprusside at a dose of 0.5 to 4 
txg" kg -1 min 1 are currently the most common medica- 
tions given in the early postoperative p riod to patients at 
high risk. These agents are administered through a right 
atrial or pulmonary arterial ine in an attempt to keep the 
pulmonary artery pressure at less than 40% of systemic 
pressure. If dopamine or epinephrine is required at a 
dosage of more than 5 /xg.kg 1 min-1, it is delivered 
through the left atrial line in an attempt o reduce the 
potential pulmonary vasoconstrictive effects. 
Prevention strategy for postoperative pulmonary hy- 
pertension. Postoperative pulmonary hypertensive events 
include pulmonary hypertensive crisis and persistent pul- 
monary hypertension. Pulmonary hypertensive crisis is 
defined as a syndrome of hyperacute rise of systolic 
pulmonary pressure (>50% of systemic pressure) accom- 
panied by a profound reduction in cardiac output and a 
fall in S~%. Persistent pulmonary hypertension is defined 
as postoperative systolic pulmonary arterial pressure more 
than 50% of systemic pressure continuing for longer than 
6 hours after repair. Patients in the high-risk diagnostic 
categories for postoperative pulmonary hypertensive 
events are paralyzed and mechanically ventilated for at 
least 24 hours. Moderate hyperventilation is used if sys- 
tolic pulmonary arterial pressure is more than 40% of 
systemic pressure. This approach to ventilator manage- 
ment and sedation has been used consistently throughout 
the 15 years covered by this report. 
Intravenous administration of chlorpromazine is begun 
in the immediate postoperative period at a dose of 0.25 
rag, adjusting it for its pulmonary vasodilatory (a-adren- 
ergic blockade) and central nervous system sedative ef- 
fects as needed to a maximum of 2 mg every 4 hours. If 
pulmonary hypertension (>50% of systemic pressure) 
persists after administration of chlorpromazine, prazosin 
(another c~-blocker) is given orally or by nasogastric tube 
beginning with 0.25 mg and adjusting up to 2 mg every 4 
hours. If a patient requires chlorpromazine or prazosin, 
then one or both are continued for 2 to 4 weeks orally 
after discharge, and the dose is gradually reduced. This 
a-blocker treatment regimen for preventing postoperative 
pulmonary hypertension was started in late 1989 and has 
been routinely used since September 1991. 
Postoperative valuation. A complete set of postoper- 
ative physiologic data was available for 796 patients (90%) 
including arterial blood gas (oxygen tension, carbon diox- 
ide tension, and pH), inotropic requirement, rhythm, 
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Table I. Incidence of postoperative pulmonary hypertensive events and hospital mortality in high-risk patient 
groups 
PHE 
Total No. of No. of early 
Diagnosis patients No. % deaths Mortality (%) 
TAPVC 90 36 40 10 l l  
Truncus arteriosus 47 14 30 11 23 
TGA 97 14 14 6 6 
VSD 414 59 14 10 2 
HLHS 50 4 8 24 48 
AV canal 182 11 6 14 8 
Total 880 138 16 75 8.5 
PHE, Pulmonary hypertensive events; TAPVC, total anomalous pulmonary venous connection; TGA, transposition of the great arteries; VSD, ventricular 
septal defect; HLHS, hypoplastic left heart syndrome; AV, atrioventricular. 
pacemaker requirement, systemic arterial and pulmonary 
arterial pressures, atrial pressures (right, left, or both), 
and right atrial and pulmonary arterial oxygen saturations. 
Evidence of significant postoperative l ft and or right 
ventricnlar dysfunction was evaluated carefully by trans- 
esophageal echocardiography. In-hospital (perioperative) 
death was defined as death occurring within 30 days of the 
operation or before discharge from the hospital after 
repair. Postoperative patient status 30 days after opera- 
tion was determined by direct evaluation of the patient by 
the pediatric ardiologist and surgeon or by letters from 
referring physicians. One month follow-up data were 
available for 844 patients (96%). 
Statistical analysis. Data were analyzed with the SAS 
software package (Statistical Analysis Systems, Cary, 
N.C.). Initially, patients at high risk for the development 
of pulmonary hypertensive events were determined ac- 
cording to the previously described efinition. Trends in 
postoperative patient management i  three time frames 
(1980 to 1984, 1985 to 1989, 1990 to 1994) were compared 
by Mantel-Haenszel X 2analysis. 
A multivariable logistic regression model was used to 
identify independent risk factors for development of 
pulmonary hypertensive events and mortality related to 
pulmonary hypertensive events in the cohort of 880 high- 
risk patients. Variables entered into risk factor analysis 
are summarized in Appendix. Selection of independent 
variables was a forward stepwise method with a critical p 
value for variable inclusion and exclusion of 0.15. The C 
statistic was used to determine model fit. 7 Calibration was 
determined by van Houwelingen and le Cessie's heuristic 
shrinkage estimate) A p value lower than 0.05 was 
considered significant. 
Results 
Incidence of postoperative pulmonary hyperten- 
sive events. Among 2484 patients with congenital 
heart disease operated on with the use of cardiopul- 
monary bypass, those with atrioventricular canal, 
truncus arteriosus, total anomalous pulmonary ve- 
nous connection, transposition of the great arteries, 
hypoplastic left heart syndrome, and ventricular 
septal defect were determined to be at high risk for 
the development ofpostoperative pulmonary hyper- 
tensive events (Table I). All of these high-risk 
groups had an incidence of pulmonary hypertensive 
events higher than 5%. In contrast, pulmonary 
hypertensive events developed in fewer than 1.5% of 
patients after definitive repair of the other low-risk 
lesions (data not shown). Although patients with left 
ventricular outflow obstruction, coarctation of aorta, 
mitral and aortic regurgitation, or anomalous origin 
of left coronary artery may have increased pulmo- 
nary vascular esistance, cases of closed operation 
and rare cases (fewer than 10 cases in this series) 
were excluded. 
Perioperative mortality and mortality related to 
pulmonary hypertensive events. Seventy-five chil- 
dren (8.5%) in these six high-risk congenital heart 
disease groups died during the perioperative period 
(Table I). The mortality rates among those patients 
within each diagnostic group in whom pulmonary 
hypertensive events developed are depicted in Table 
II. Overall, 23% of patients in whom pulmonary 
hypertensive vents developed uring the last 15 
years of our experience died. 
Trends in postoperative management. Trends in 
the evolution of postoperative management are 
summarized in Table III. Routine monitoring of 
S~?o 2was initiated in September 1986; monitoring of 
postoperative pulmonary arterial pressure began in 
June 1984. Since August 1990, intraoperative trans- 
esophageal echocardiography as been used rou- 
tinely to assess the completeness of the repair of 
complex congenital heart disease. 
Trends in incidence of and mortality rates asso- 
ciated with pulmonary hypertensive events. The 
incidence of pulmonary hypertensive vents de- 
clined significantly, from 30.5% (1980 to 1984) to 
6.8% (1990 to 1994). Although the overall early 
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mortality rate did not change, the early mortality 
rate associated with pulmonary hypertensive events 
declined substantially, from 5.7% (1980 to 1984) to 
2.4% (1990 to 1994). Moreover, pulmonary hyper- 
tension was the primary cause of early death (71%, 
10/14 patients at risk) in 1980 to 1984, but this rate 
had declined significantly to 29% (11/38 patients at 
risk) in 1990 to 1994. 
Risk factors for development of pulmonary hyper- 
tensive events. Factors associated with develop- 
ment of postoperative pulmonary hypertensive 
events were analyzed by univariate and logistic 
regression analyses. By univariate analysis, absence 
of S~'o 2monitoring (p < 0.0001), absence of prophy- 
laxis with a-blockers (p < 0.0001), preoperative 
pulmonary hypertension (p < 0.0001), and prema- 
turity (p = 0.02) were significant risk factors. By 
multivariable logistic regression, preoperative pul- 
monary hypertension, absence of $9o 2 monitoring, 
and absence of prophylaxis with a-blockers were 
independent risk factors for the development of 
postoperative pulmonary hypertensive events (Ta- 
ble IV). 
Risk factors for early death associated with pul- 
monary hypertensive vents. By univariate analysis, 
year of operation (p = 0.06), aortic crossclamp time 
(p = 0.02), monitoring of pulmonary arterial pres- 
sure (p = 0.06), preoperative pulmonary hyperten- 
sion (p = 0.01), and prophylaxis with a-blockers 
(p = 0.007) were identified as risk factors for 
in-hospital death associated with pulmonary hyper- 
tensive vents. With a multivariable ogistic regres- 
sion model, preoperative pulmonary hypertension, 
absence of prophylactic a-blockade, and monitoring 
of pulmonary arterial pressure were identified as 
independent risk factors for in-hospital death asso- 
ciated with pulmonary hypertensive events (Table 
V). 
Impact of timing of definitNe repair on develop- 
ment of pulmonary hypertensive events. Because 
early definitive repair, before the development of
significant histologic hanges in the pulmonary ar- 
teries, may reduce the incidence of postoperative 
pulmonary hypertension, each high-risk diagnostic 
category was subdivided according to the patient's 
age at repair for comparison of incidences of post- 
operative pulmonary hypertensive vents (Table 
VI). Except in the total anomalous pulmonary ve- 
nous connection group, the incidence of pulmonary 
hypertension was higher among patients who under- 
went repair at an older age. To determine whether 
timing of the repair might have impacted the devel- 
Table II. Hospital mortality associated with 
pulmonary hypertensive events 
Early deaths PHE 
associated with 
Diagnosis PHE No. % 
HLHS 4 4 100.0 
AV canal 6 11 54.5 
Truncus arteriosus 7 14 50.0 
TGA 3 14 21.4 
TAPVC 6 36 16.7 
VSD 5 59 8.5 
Total 31 138 22.5 
PHE, Pulmonary hypertensive events; HLHS, hypoplastic left heart syn- 
drome; AV, atrioventricular; TGA, transposition of the great arteries; 
TAPVC, total anomalous pulmonary venous connection; VSD, ventricular 
septal defect. 
opment of postoperative pulmonary hypertensive 
events, patients with total anomalous pulmonary 
venous connection were excluded. Risk factors for 
the development of pulmonary hypertensive events 
were then reanalyzed. By multivariable logistic re- 
gression, definitive repair at older age, absence of 
S~7o2 monitoring, and preoperative pulmonary hy- 
pertension were all significant risk factors for the 
development of pulmonary hypertension (Table 
VII). 
Discussion 
Reactive or persistent pulmonary hypertension 
has been one of the most significant causes of 
morbidity and mortality after operation for congen- 
ital heart disease. Only a few studies have attempted 
to elucidate the risk factors, pathophysiology, and 
management of postoperative pulmonary hyperten- 
sion.9, 10 It has been difficult to determine which 
patients with which specific congenital cardiac le- 
sions will have postoperative pulmonary vascular 
disease. 11 This study was performed to determine 
the incidence of and risk factors for the develop- 
ment of this complication i different categories of 
congenital heart defects and to analyze the impact 
on outcome of changes in monitoring and manage- 
ment. 
This study confirms several important clinical 
impressions that those of us involved in congenital 
heart surgery have "known" for a long time. First, 
preoperative pulmonary hypertension is the most 
significant risk factor for the development of post- 
operative pulmonary hypertensive events and deaths 
related to this complication (Tables IV and V). 
Second, patients with atrioventricular canal, truncus 
arteriosus, transposition of the great arteries, ven- 
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Table III. Trends in postoperative management, incidence of pulmonary hypertensive events, and mortality of 
patients at high risk between 1980 and 1994 
1980-1984 1985-1989 1990-1994 
(n = 177) (n = 246) (n = 457) 
No. % No. % No. % p 
S?o2 monitoring 1 0.6 186 75.6 457 100.0 <0.001 
PAP monitoring 12 6.8 115 46.8 327 71.6 <0.001 
NTG/nitroprusside treatment 18 10.2 36 14.6 156 34.1 <0.001 
CP/PR prophylaxis 0 0.0 5 2.0 263 57.5 <0.001 
Incidence of PHE 54 30.5 53 21.5 31 6.8 <0.001 
Early mortality associated with PHE 10 5.7 14 5.7 11 2.4 0.076 
Early mortality 14 7.9 23 9.4 38 8.3 0.861 
PAP, Pulmonary arterial pressure; NTG, nitroglycerin; PHE, pulmonary hypertensive events. 
Table IV. Risk factors for development ofpulmonary hypertensive events according to multivariable logistic 
regression 
Wald confidence limits 
Factors p Odds ratio Lower Upper 
Preoperative PH <0.0001 11.53 7.32 18.15 
CP/PR prophylaxis 0.0004 0.36 0.20 0.63 
S?oz monitoring <0.0001 0.35 0.22 0.57 
C statistics 0.81; X 2 for covariates 173.67 with 3 degrees of freedom (p = 0.0001). PH, Pulmonary hypertension; CP,chlorpromazine; PR, prazosin. 
Table V. Risk factors for early death associated with pulmonary hypertensive events according to multivariable 
logistic regression 
Wald confidence limits 
Factors p Odds ratio Lower Upper 
PAP monitoring 0.03 2.51 1.10 5.75 
Preoperative PH 0.036 2.20 1.05 4.59 
ACC time 0.055 1.01 1.00 1.02 
CP/PR prophylaxis 0.009 0.26 0.09 0.71 
C statistics 0.74; X 2 for covariates 23.94 with 4 degrees offreedom (p = 0.0001). PAP, Pulmonary arterial pressure; PH, pulmonary h pertension;ACC, aortic 
crossclamp; CP, chlorpromazine; PR, prazosin. 
tricular septal defect, hypoplastic left heart syn- 
drome, and total anomalous pulmonary venous 
connection are at high risk for the subsequent 
development of pulmonary hypertensive events. 
Hypoxemia, hypercapnia, metabolic acidosis, rest- 
lessness, and tracheal suctioning may increase pul- 
monary vasoreactivity and thus trigger postoperative 
pulmonary hypertensive events. 12 Moderate hyper- 
ventilation with a high fraction of inspired oxygen 
and sedation and paralysis during the first 24 to 48 
hours after operation have been basic strategies in 
our management of these cases during the last 15 
years of our experience. Even when all these precip- 
itating factors could be avoided, pulmonary hyper- 
tensive vents till occurred in some patients. It has 
been our clinical experience that pulmonary arterial 
pressures and central venous pressure gradually 
increase and 890 2 decreases before severe pulmo- 
nary hypertensive crises occur. Both the severity of 
pulmonary hypertension and right ventricular fail- 
ure in patients with persistent pulmonary hyperten- 
sion were accurately monitored by these indexes. 13 
We therefore initiated routine monitoring of Svo 2 
and pulmonary arterial pressures in the middle to 
late 1980s in an attempt to detect he earliest stages 
of a pulmonary hypertensive crisis and to avoid 
irreversible changes from persistent pulmonary hy- 
pertension (Table III). 
Preventive strategies have also evolved during 
the last 15 years. Prophylactic administration of 
a-blockers and nitroglycerin or nitroprusside has 
been routinely used during the last 5 years for 
patients at high risk. Along with improved monitor- 
ing and preventive techniques, the incidence of 
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Table VI. Impact of timing of definitive repair on postoperative pulmonary hypertensive events 
Timing of definitive repair 
Prevalence of PHE 
Early repair Late repair 
Diagnosis Early Late No. % No. % 
HLHS -<30 days >30 days 1/45 2.2 3/5 60.0 
Truncus arteriosus -<30 days >30 days 2/14 14.3 12/33 36.4 
TAPVC -<30 days >30 days 24/48 50.0 12/42 28.6 
TGA -<2 wk >2 wk 2/30 6.7 12/67 17.9 
VSD -<6 mo >6 mo 4/45 8.9 55/369 14.9 
AV canal -<6 mo >6 mo 2/41 4.9 9/141 6.4 
PHE, Pulmonary hypertensive events; HLHS, hypoplastic left heart syndrome; TAPVC, total anomalous pulmonary venous connection; TGA, transposition 
of the great arteries; VSD, ventricular septal defect; AV, atrioventricular. 
Table VII. Risk factors for development ofpulmonary hypertensive events according to multivariable logistic 
regression, with patients with total anomalous pulmonary venous connection excluded 
Wald confidence limits 
Factors p Odds ratio Lower Upper 
Preoperative PH <0.0001 9.13 5.65 14.77 
Definitive repair at older age 0.031 2.24 1.08 4.65 
CP/PR prophylaxis 0.142 0.62 0.32 1.18 
S~)o 2monitoring 0.002 0.43 0.25 0.73 
C statistics 0.78; X 2 for covariates 117.82 with 4 degrees of freedom (p = 0.0001). P//, Pulmonary hypertension; CP, chlorpromazine; PR, prazosin. 
pulmonary hypertensive events has declined signifi- 
cantly, from 31% (1980 to 1984) to 6.8% (1990 to 
1994,p < 0.001; Table III). Moreover, the mortality 
rate associated with pulmonary hypertensive events 
among patients in whom pulmonary hypertension 
developed has declined significantly (71% 1980 to 
1984 to 29% 1990 to 1994). 
By multivariable logistic regression, preoperative 
pulmonary hypertension was found to be the most 
significant predictor of postoperative pulmonary hy- 
pertensive vents (Table IV). Previous pulmonary 
artery banding did not have a significant negative 
impact on the development ofpostoperative pulmo- 
nary hypertensive events. Absence of S~?o a monitor- 
ing and absence of prophylactic a-blockers were 
additional independent risk factors for the develop- 
ment of subsequent pulmonary hypertensive events. 
Furthermore, preoperative pulmonary hypertension 
and absence of prophylactic a-blockade were also 
independent risk factors for death associated with 
pulmonary hypertension. Although monitoring of 
pulmonary arterial pressure was associated with an 
increased risk of postoperative pulmonary hyperten- 
sive events, this may simply be a reflection of the fact 
that patients with preoperative pulmonary hyperten- 
sion are most likely to have pulmonary arterial 
pressures monitored. 
Pulmonary artery vasodilator therapy with 
a-blockers is nonselective and could produce sys- 
temic hypotension, leading to an increase in mor- 
bidity. 14 We have not seen a significant mortality 
rate associated with our treatment regimen, how- 
ever, which includes tarting chlorpromazine, prazo- 
sin, or both at minimal dosage (0.25 rag) and 
adjusting up to 2 mg of each. Mild systemic hypo- 
tension (<5%) did occur in some patients, but this 
was only observed with the first or second dose, and 
volume supplements were adequate treatment in 
most cases. Because nitric oxide is a selective pul- 
monary vasodilator in neonates and infants, we plan 
to initiate a randomized trial of inhaled nitric oxide 
versus conventional prophylaxis with a-blockers and 
nitrovasodilators a the first-line treatment for post- 
operative pulmonary hypertension. 
The impact of the timing of definitive repair on 
morbidity and mortality related to pulmonary hyper- 
tensive events was specifically addressed in this 
study (Table VI). Delayed definitive repair in pa- 
tients with a left-to-right shunt (atrioventricular 
canal, truncus arteriosus, ventricular septal defect) 
or patients with ductus-dependent circulation 
(transposition of great arteries, hypoplastic left 
heart syndrome) resulted in a higher incidence of 
pulmonary hypertensive events than seen with de- 
finitive early repair (p = 0.006 by Fisher's Exact 
Test). These results are consistent with other large 
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retrospective s ries and support he concept of early 
definitive repair, before irreversible pulmonary vas- 
cular remodeling occurs, t-6 In contrast, among pa- 
tients with total anomalous pulmonary venous con- 
nection, neonates had a higher incidence of 
pulmonary hypertension than did patients older 
than 30 days (p = 0.052 by Fisher's Exact Test). This 
difference probably reflects the fact that patients 
with poor preoperative conditions associated with 
severe pulmonary venous obstruction require emer- 
gency operation as neonates, 15' 16 and these patients 
are more likely to have postoperative pulmonary 
hypertensive events. Patients at high risk with total 
anomalous pulmonary venous connection also re- 
quire neonatal repair. The recent excellent results of 
neonatal repair for this anomaly support his inter- 
pretation.3, 17, 19 
Although the mechanism of development of pul- 
monary hypertension remains unclear, recent stud- 
ies have indicated that vasoactive mediators, includ- 
ing endothelin-1, may play an important role. 2°' 2i 
Interestingly, McGowan and associates 21found that 
plasma concentrations of endothelin-1 are signifi- 
cantly higher in neonates with transposition of the 
great arteries than in patients with atrial septal 
defects, both before and after cardiopulmonary b - 
pass. These findings may explain in part why patients 
with transposition may be more vulnerable to post- 
operative pulmonary hypertension than those with 
atrial septal defects. The relative roles in different 
cardiac anomalies of endothelin-1 and other vaso- 
active mediators, as well as the roles of endogenous 
and exogenous nitric oxide, require further study to 
elucidate the exact mechanism of postoperative 
pulmonary hypertensive events. 
This retrospective study, which was based on a 
15-year single-institution experience, has certain 
limitations. First, although the mechanism, inci- 
dence, and risk factors may be different for pulmo- 
nary hypertensive crisis and persistent pulmonary 
hypertension, it was impossible to clearly differenti- 
ate between these two complications because of the 
limits of retrospective r view. Second, rare diseases 
(fewer than 10 cases in our series) such as aorto- 
pulmonary window, anomalous left coronary arter- 
ies, congenital mitral disease, and congenital pulmo- 
nary vein stenosis without total anomalous 
pulmonary venous return were excluded to reduce 
the risk of the type II error in statistical analysis, but 
these diseases may still represent high-risk catego- 
ries for postoperative pulmonary hypertension. 15 
Third, other factors such as hypothermia, restless- 
ness, and tracheal suctioning are believed to trigger 
pulmonary hypertensive events, 22 but these possible 
risk factors could not be incorporated into this 
analysis as a result of inconsistencies in the data. 
In summary, patients with atrioventricular canal, 
truncus arteriosus, transposition of the great arter- 
ies, hypoplastic left heart syndrome, ventricular 
septal defect, and total anomalous pulmonary ve- 
nous connection are at high risk for the develop- 
ment of postoperative pulmonary hypertensive 
events. Multivariable logistic regression analysis re- 
vealed that preoperative pulmonary hypertension, 
absence of S?02 monitoring, absence of prophylaxis 
with a-blockers (chlorpromazine or prazosin), and 
definitive repair at an older age are significant risk 
factors for the development ofpostoperative pulmo- 
nary hypertension and for early death related to this 
complication. We conclude that monitoring of $902 
and prophylactic a-blockade significantly reduce the 
incidence of pulmonary hypertensive vents after 
operation for congenital heart disease. Definitive 
early repair reduces the postoperative morbidity and 
mortality from pulmonary hypertensive events. Fur- 
ther clinical trials of inhaled nitric oxide and studies 
to elucidate the mechanism of pulmonary hyperten- 
sion are necessary if we are to completely under- 
stand and eliminate this severe complication. 
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Discuss ion 
Dr. Pedro del Nido (Boston, Mass.). I commend you for 
a thorough retrospective r view of this important clinical 
problem. I would like to make some comments on some 
issues that you brought up, which I believe are very 
important, and also ask some questions. 
First, I think we would concur with your conclusions 
that in the ease of children with large, symptomatic 
left-to-right shunts, delaying corrective procedures in an 
effort to "allow the child to grow or decrease the risk of 
surgery" may in fact increase the risk of operative repair, 
primarily from complications related to pulmonary hyper- 
tension. At Boston Children's Hospital, we continue to 
advocate a policy of early repair for all patients with large 
left-to-right shunts that are unlikely to spontaneously 
resolve. 
Second, when discussing pulmonary hypertension i
children, it is important o differentiate between high 
pulmonary vascular esistance and pulmonary reactivity. 
The first is usually seen in children with long-standing 
left-to-right shunts or pulmonary venous hypertension. 
The second, however, can also be seen in neonates within 
the first 24 hours after cardiopulmonary bypass. The latter 
we usually treat with sedation and occasionally with 
muscle relaxants and by minimizing noxious timuli such 
as suctioning. 
The former problem, however, increased pulmonary 
vascular resistance, is more serious. It is usually treated in 
our institution with moderate hyperventilation. I  cases 
where low cardiac output is seen, we would use inhaled 
nitric oxide as a locally active specific pulmonary antihy- 
pertensive. 
In an analysis of the first 225 children who were treated 
at Children's Hospital with nitric oxide as an agent to 
decrease their pulmonary resistance, about a third of the 
patients were neonates. However, this spans the gamut of 
all ages and all diagnoses. 
What we found is that in fact there are certain catego- 
ries that respond much better. As you would expect, 
patients with Eisenmenger's disease have very little re- 
sponse; however, patients with pulmonary venous hyper- 
tension, that is total anomalous pulmonary venous return, 
mitral valve disease, or elevated left atrial pressures from 
cardiomyopathy, responded quite well and were in fact the 
best group. 
My questions to you are several. First, can you differ- 
entiate for us whether your technique of using c~-blockers 
is effective for treating pulmonary hypertension, that is, 
increased pulmonary vascular resistance alone, or is it also 
effective in preventing the pulmonary hypertensive crises 
that you describe? 
Second, there are inherent limitations in a retrospective 
review such as this one; however, was there a concurrent 
shift toward younger corrections in this patient popula- 
tion, and was that shift also at a similar time frame as 
when you initiated your a-blocker program? In other 
words, can you differentiate for us whether these two were 
independent variables? 
Third, you included in your analysis children with 
transposition f the great arteries, agroup in whom repair 
is delayed unless they have a large ventricular septal 
defect and that is usually not considered at risk for 
pulmonary hypertension. Can you tell us what your ratio- 
nale was for including these patients? Have you analyzed 
your data excluding this group to see whether the results 
are the same? 
Finally, the groups that you identified as being at 
highest risk for postoperative pulmonary hypertension 
were those with atrioventricular canal, truncus arteriosus, 
and ventricular septal defect. On the basis of your analy- 
sis, can you speculate for us regarding how much impact 
earlier repair would have had on preventing pulmonary 
hypertension, versus the strategy of using complex phar- 
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macologic manipulations to treat children after a late 
repair? 
Dr. Bando. Your first question is whether c~-blocker 
prophylaxis is effective for both persistent pulmonary 
hypertension and pulmonary hypertensive crisis or effec- 
tive for only one of them. Because this is retrospective 
analysis based on our 15-year experience, it is difficult to 
differentiate these two categories. Our treatment strategy is
pretty much the same for persistent pulmonary hypertension 
and pulmonary hypertensive crisis. Moderate hyperventila- 
tion with a high inspired oxygen fraction, sedation, and 
paralysis have been used consistently for prevention of these 
complications for the last 15 years. Since 1990, c~-blockers 
have been used in addition to prevent both of these compli- 
cations. It is thus quite difficult to know the impact of 
c~-blockers in each of these two categories. 
Related to your question, I also would like to tell you 
one thing that I was not able to incorporate in this study. 
When pulmonary arterial pressure normalized immedi- 
ately after operation, these patients were more likely to 
have pulmonary hypertensive events, presumably a pul- 
monary hypertensive crisis. I believe that we are properly 
treating persistent pulmonary hypertension, but it may be 
that we are undertreating some patients at risk for pul- 
monary hypertensive crises. 
Your second question whether early definitive repair 
and c~-blocker prophylaxis can be differentiated as inde- 
pendent risk factors. The answer is yes. By multivariable 
logistic regression analysis, these two indexes came out as 
independent risk factors. 
Your third question is why we included transposition of
the great arteries and intact ventricular septum. Actually, 
among 97 patients with transposition of the great arteries, 
70 patients had intact ventricular septum and 27 had 
ventricular septal defects. Surprisingly, both groups had a 
relatively high incidence (75%) of pulmonary hyperten- 
sive events (8/70 [11%] for transposition of the great 
arteries with intact ventricular septum and 6/27 [22%] for 
transposition of the great arteries with ventricular septal 
defect). Currently, we are analyzing risk factors for pul- 
monary hypertensive events in each diagnostic group, and 
this further analysis may tell us the risk factors within each 
diagnostic group. 
Your last question is related to the relative impacts of 
early repair and c~-blocker prophylaxis on the develop- 
ment of postoperative pulmonary hypertensive vents. 
Because the majority of high-risk patients after 1990 had 
prophylaxis, it is difficult to stratify the patients on the 
basis of the timing of the operation. I can say, however, 
that early definitive repair is probably the best measure 
for the prevention of pulmonary hypertensive events. 
Dr. Richard A. Hopkins (Washington, D.C.). I concur 
with the praise for this study in terms of the volume and 
the amount of work it represents. We did a similar study 
in 1984 and 1985, when I was at Great Ormond Street, 
when the pediatric size oximetric catheter first became 
available, and many of our findings were exactly as you 
have found, with a couple of differences. We had the 
additional advantage of having a frequency modulated 
(FM)-type record so that we could, in fact, relate nursing 
events to the crises. 
We found at that time that patients with atrioventricu- 
lar canals were a particularly high-risk group, unlike yours. 
Of course, at that time the fashion was to operate on these 
children at around 1 year of age. Subsequent to that 
experience, I have been operating on them at between 3 
and 5 months of age. Although we see hyperreactivity, he 
crisis events with falling systemic output have virtually 
disappeared. I wonder whether you have seen that same 
change with time as you have decreased age at operation. 
Second, in that article that we published in our sister 
organization's journal, the European Journal of Cardiotho- 
racic Surgery, we defined pulmonary hypertensive crisis 
not as a rise above 50% of systemic pressure but as a rise 
to or exceeding systemic pressure, partly because so many 
of these children already have pulmonary artery pressures 
that ride around the 50% to 60% level anyway. That has 
a practical feature as well. If in fact the critical component 
is the fall in the systemic output and not the pulmonary 
artery pressure per se, you limit overdiagnosis of this 
entity. One of the problems in a pediatric intensive care 
unit is that the staff can become very frightened about 
hyperreactivity of the pulmonary artery pressure, and you 
can end up with patients being kept on hyperventilation 
for a prolonged period when what you are dealing with is 
hyperreactivity rather than true crises. Have you found the 
lower pressure definition to be problematic when attempt- 
ing to wean these children from suppressive therapy? 
Dr. Bando. As indicated in my presentation, the inci- 
dence of pulmonary hypertensive events in patients with 
atrioventricular canal was less than we expected, presum- 
ably because all these patients had c~-blocker prophylaxis 
and, more recently, underwent repair before the age of 6 
months. I also stress that once pulmonary hypertensive 
events occurred in patients with atrioventricular canal, the 
mortality rate was high (6/11, 54.5%). Regarding the 
definition of postoperative pulmonary hypertensive crisis 
versus ongoing pulmonary hypertension on the basis of a 
retrospective chart review, a prospective study is certainly 
important o identify the risk factors for pulmonary hy- 
pertensive vents. I believe, however, that it is still difficult 
to predict whether hyperreactivity will progress to "true" 
pulmonary hypertensive crisis. 
Appendix: Potential risk factors for the 
development of pulmonary hypertension, overall 
operative mortality, and mortality related to 
pulmonary hypertension 
A. Preoperative risk factors 
1. Age at repair 
2. Sex 
3. Year of operation 
4. Weight at repair 
5. Prematurity 
6. Other cardiac lesions 
7. Other noncardiac problems 
8. Previous palliation (pulmonary artery banding, 
other palliations) 
9. Preoperative pulmonary hypertension 
B. Intraoperative risk factors 
1. Total cardiopulmonary b pass 
2. Circulatory arrest ime 
3. Aortic crossclamp time 
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4. Inotropic support (dopamine, dobutamine, epi- 
nephrine; graded) 
5. Nitroglycerin or nitroprusside; graded 
6. Intraoperative transesophageal echocardiogra- 
phy 
C. Postoperative risk factors 
1. Monitoring 
a. Pulmonary arterial pressure 
b. Pulmonary arterial saturation 
c. Right atrial pressure 
d. SVO 2 
e. Systemic pressure 
f. Arterial blood gas values (oxygen tension, car- 
bon dioxide tension, pH) 
2. Management 
Bando et al. 1609 
a. Inotropic support (dopamine, dobutamine, pi- 
nephrine; graded) 
b. Nitroglycerin or nitroprusside; graded 
c. Prophylaxis with chlorpromazine or prazosin 
d. Delayed sternal closure 
3. Results 
a. Pulmonary hypertensive events (pulmonary hy- 
pertensive crisis or persistent pulmonary hyper- 
tension) 
b. Hospital mortality 
c. Hospital mortality associated with pulmonary 
hypertensive events 
d. Late mortality 
e. Current New York Heart Association func- 
tional class 
